本文へ移動
cccskills
無料GitHub で公開

es-cushing-treatment-goals-overt-cs

This skill defines the treatment goals for patients with overt Cushing's syndrome, focusing on normalizing cortisol levels or action to eliminate symptoms and treat comorbidities. Use when a clinician asks about treatment objectives for a newly diagnosed overt Cushing's syndrome patient; triggers include "overt CS," "treatment goals for overt Cushing's," and "normalize cortisol in overt CS."

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md2.8 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Treatment Goals for Overt Cushing's Syndrome

STEP 1 — Gather Information

Confirm diagnosis of overt Cushing's syndrome via clinical features (e.g., weight gain, hypertension, diabetes, skin changes) and biochemical tests (24‑h UFC > upper limit of normal, late‑night salivary cortisol > normal, or abnormal dexamethasone suppression test). Assess baseline comorbidities (hypertension, diabetes, dyslipidemia, osteoporosis, psychiatric symptoms) and current medications.

STEP 2 — Rule In / Rule Out

Rule in overt CS if biochemical hypercortisolism is present with specific signs/symptoms; rule out if only borderline biochemical abnormality of the HPA axis without any clinical manifestations of CS, as treatment is not recommended in that setting.

STEP 3 — Classify or Stratify

Classify postoperative or pretreatment cortisol status as hypercortisolemic (persistent elevated UFC or late‑night cortisol), eucortisolism (normal cortisol), or hypocortisolemic (low cortisol with symptoms of adrenal insufficiency). Persistent hypercortisolism after initial therapy indicates need for additional intervention.

STEP 4 — Decide

If hypercortisolism persists, initiate additional treatments (medical therapy, bilateral adrenalectomy, repeat transsphenoidal surgery, or radiation) aimed at normalizing cortisol; if eucortisolism is achieved, maintain cortisol normalization, treat comorbidities, and schedule lifelong surveillance for recurrence.

Clinical Guardrails / Mimics / Pitfalls

Do not treat based solely on borderline biochemical abnormalities without clinical signs; avoid overtreatment that may cause iatrogenic adrenal insufficiency; monitor for glucocorticoid withdrawal symptoms after surgery; address cortisol‑dependent comorbidities aggressively even when cortisol is normalized.

Concrete Clinical Example

A 48‑year‑man presents with progressive weight gain, new‑onset hypertension, and uncontrolled diabetes; 24‑h UFC is 6× ULN and late‑night salivary cortisol is elevated. Diagnosis of overt corticotropin‑secreting pituitary adenoma is confirmed. Treatment goal: normalize cortisol via transsphenoidal surgery, control hypertension and diabetes with adjunctive meds, and monitor postoperative cortisol and symptoms for remission.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI:10.1210/jc.2015-1818

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する